Asieris Pharmaceuticals Announces 2021 Annual Report: Steady Progress in Core Product Pipeline and Progressive Implementation of the Integrated Diagnosis and Treatment Commercialization Strategy
SHANGHAI, April 14, 2022 /PRNewswire/ -- Asieris Pharmaceuticals (688176.SH), a global innovative pharmaceutical company specializing in the treatment of genitourinary cancers and related major diseases, announced its 2021 annual report today. The company is currently making steady progress in multiple global clinical trials for its core investigational drugs and is actively implementing its integrated diagnosis-treatment strategy for commercialization. In...
Canton Fair 2022: Technological Innovation Steers Medical Industry Towards Golden Age
GUANGZHOU, China, April 14, 2022 /PRNewswire/ -- The 131st Canton Fair is open from April 15 to April 24. The Health section at the 131st Canton Fair is fully prepared in the expectation of a plenty of orders, as it attracted much attention from global buyers in the last session. Maggie Pu, Deputy Director General of the Foreign Affairs Office...
Clarin.com: Here are the 12 Argentinian doctors and researchers making the biggest international impact
BUENOS AIRES, Argentina, April 14, 2022 /PRNewswire/ -- The work of Argentine doctors and researchers is impacting other parts of the world. The research and analysis carried out by the firm Key Opinion Leaders and available at https://www.keyopinionleaders.com/ quantifies Argentinian researchers' level of impact within the scientific community for specific concepts. The complete list for each specialty shows some...
DEBIOPHARM ANNOUNCES ONCOLOGY RESEARCH ADVANCEMENTS AT AACR 2022 FOR NOVEL CANCER COMPOUNDS AND DRUG DELIVERY TECHNOLOGIES
Pre-clinical & clinical exploratory poster presentations to highlight oncology results with Debio 0123, xevinapant, and Multilink™ technology for antibody drug conjugates LAUSANNE, Switzerland, April 14, 2022 /PRNewswire/ -- Debiopharm, (www.debiopharm.com/debiopharm-international/) an oncology and infectious disease focused biopharmaceutical company based in Switzerland, today announced data releases on 3 investigational products including Debio 0123 (Selective WEE1 inhibitor), clinical exploratory results for...
CDD Vault Integrates with SnapGene Server for Web-Based Sharing of Plasmid Information
BURLINGAME, Calif. and SAN DIEGO, April 14, 2022 /PRNewswire/ -- Collaborative Drug Discovery, Inc. (CDD) announced today that it has completed the integration of SnapGene Server with its flagship CDD Vault research informatics platform. This integration allows users to visualize and share plasmid information such as maps and sequences within the web-based CDD...
Gracell Biotechnologies’ Abstract on GC012F, a BCMA/CD19 Dual-targeting CAR-T Cell Therapy, Accepted for Presentation at 2022 ASCO Annual Meeting
PALO ALTO, Calif. and SUZHOU, China, April 14, 2022 /PRNewswire/ -- Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced that its abstract providing the follow-up clinical data of GC012F in...
China Medical System (0867.HK): the Leader in Commercialization Embraces Great Industry Opportunities as Biotech Companies are Eager to Monetize Their Innovative Products
HONG KONG, April 14, 2022 /PRNewswire/ -- Recently, China Medical System ("CMS", 0867.HK) announced its annual results. After recording continuous performance growth in the difficult time of the pandemic in 2020, it once again achieved a new record high, with revenue of RMB 8,337 million, up 20.0% year-on-year, and net profit of RMB 3,025 million, up 18.4% year-on-year. In addition...
Fosun Diagnostics Receives China NMPA Approval for Its Independently Developed Novel Coronavirus Antigen Detection Kit Amidst of The National Efforts in Pandemic Prevention and Control
SHANGHAI, April 14, 2022 /PRNewswire/ -- April 13, 2022, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ("Fosun Pharma" or "the Group"; Stock Code: 600196.SH, 02196.HK) announced that the Novel Coronavirus (2019-nCoV) Antigen Detection Kit (Colloidal Gold) self-developed by Fosun Diagnostics Co., Ltd. ("'Fosun Diagnostics"), a subsidiary company of Fosun Pharma has received approval from the China's National Medical Products Administration (NMPA)...
First Patients Dosed with Illuccix® – Telix’s Approved Prostate Cancer Imaging Agent
Physicians in Indiana, New York City, and Washington are among the first to administer Illuccix® – demonstrating coast-to-coast availability of this new imaging agent Typically diagnosed in men over 50, prostate cancer is the second leading cause of cancer death in American men, after lung cancer INDIANAPOLIS, April 14, 2022...
International Team Led by BGI Completes First Whole-Body Cell Atlas of a Non-Human Primate
The research will provide insights into the development of potential treatments for neurological diseases and obesity, among other human conditions. SHENZHEN, China, April 14, 2022 /PRNewswire/ -- In a breakthrough that could lead to scientific advancement in the treatment of human diseases, researchers from BGI-Research, together with scientific research teams from China, Germany, Italy, Singapore, Spain, Sweden and the...
